Clinical characteristics and outcomes of patients with cryptococcal meningoencephalitis in a resource-limited setting

J Med Assoc Thai. 2014 Mar:97 Suppl 3:S26-34.

Abstract

Background: Cryptococcosis is a potentially lethal opportunistic infection among human immunodeficiency virus (HIV)-infected individuals. The mortality rate of patient with cryptococcal meningoencephalitis (CM) in Thailand is high. Studying the factors associated with treatment failure is important to improve outcome.

Material and method: A retrospective study of patients with cryptococcosis in Siriraj Hospital, Thailand, during 2005-2008 was conducted. Treatment options, outcomes, survival and factors associated with outcomes and mortality were analyzed.

Results: A total of 143 patients with cryptococcosis were enrolled. Mean age was 39 years old and 58.7% were male. There were 124 HIV-infected patients (86.7%) and 116 of those had CM. Favorable clinical response in HIV-associated CM was 55.2% and 6-month survival was 67.2%. Relapse was found in 21 patients (18.1%). Factors associated with favorable clinical response included lower opening and closing pressures and a higher white blood cell in cerebrospinal fluid (CSF). Favorable mycological response was 56.8% and factors associated with favorable mycological response were a lower CD4+ T-lymphocyte count and a longer amphotericin B treatment. The median time to achieve CSF sterilization was 30 days. Factors associated with survival were a longer course of amphotericin B, a lower CSF opening pressure and a higher white blood cell in CSF.

Conclusion: High mortality rate of HIV-associated CM was demonstrated and most likely linked to inadequate induction antifungal therapy resulting in inability to sterilize CSF. New strategies and/or guidelines are suggested to improve survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / microbiology
  • AIDS-Related Opportunistic Infections / mortality*
  • Adult
  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Cryptococcosis / diagnosis
  • Cryptococcosis / drug therapy
  • Cryptococcosis / mortality*
  • Female
  • Humans
  • Male
  • Meningitis, Cryptococcal / drug therapy
  • Meningitis, Cryptococcal / mortality*
  • Meningoencephalitis / drug therapy
  • Meningoencephalitis / microbiology*
  • Meningoencephalitis / mortality*
  • Middle Aged
  • Retrospective Studies
  • Thailand / epidemiology
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Amphotericin B